Showing results (191-200 of 225) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 1997
CD30 ligand in lymphoma patients with CD30+ tumorsA Younes, U Consoli, V Snell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Paclitaxel (Taxol) for the treatment of lymphomaA Younes, J P Ayoub, A Sarris, et al.
Oncology (Williston Park, N.Y.)|August 11, 2001
Irinotecan in relapsed or refractory non-Hodgkin's lymphomaA H Sarris, J Romaguera, F B Hagemeister, et al.
Bioorganic Chemistry|March 3, 2020
Antiproliferative activity of cycloalkanecarboxamide derivatives possessing sulfonate or sulfamate moietyMohammed I El-Gamal, Hany A Omar, Mohammad H Semreen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphomaA H Sarris, A Younes, P McLaughlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC seriesA López-Guillermo, F Cabanillas, P McLaughlin, et al.
British Journal of Haematology|February 1, 1997
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trialA Younes, J P Ayoub, A Sarris, et al.
Blood|May 16, 1998
The clinical significance of molecular response in indolent follicular lymphomasA López-Guillermo, F Cabanillas, P McLaughlin, et al.
Pageof 23